Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I

Journal of Hepatology

Volumn 63, Issue 2, 2015, Pages 329-336

  Berraondo, Pedro ^a   Di Scala, Marianna ^a   Korolowicz, Kyle ^b   Thampi, Linta M ^b   Otano, Itziar ^a   Suarez, Lester ^a   Fioravanti, Jessica ^a   Aranda, Fernando ^a   Ardaiz, Nuria ^a   Yang, Junming ^b   Kallakury, Bhaskar V ^b   Tucker, Robin D ^b   Vasquez, Marcos ^a   Menne, Stephan ^b   Prieto, Jesús ^a   González Aseguinolaza, Gloria ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antivirals; Chronic hepatitis B; Genetic transfer; IFN hematological toxicity; Woodchuck

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; APOLIPOPROTEIN A1; ENTECAVIR; RNA; VIRUS DNA; VIRUS RNA; ANTIVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GENE THERAPY; HEPADNAVIRUS INFECTION; HEPATITIS B VIRUS; IMMUNOSTIMULATION; LIVER DIRECTED GENE THERAPY; MOUSE; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIREMIA; VIRUS LOAD; WOODCHUCK; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE VECTOR; GENETICS; HEPADNAVIRIDAE; HEPATITIS B, CHRONIC; LIVER; METABOLISM; PROCEDURES; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; APOLIPOPROTEIN A-I; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HEPADNAVIRIDAE; HEPATITIS B, CHRONIC; INTERFERON-ALPHA; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84942836035     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.048     Document Type: Article

References (20)

1. Ioannou GN. Chronic hepatitis B infection: a global disease requiring global strategies. Hepatology 2013;58:839-843.
2. Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 2013;58:890-901.
3. EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
4. Fioravanti J, Gonzalez I, Medina-Echeverz J, Larrea E, Ardaiz N, Gonzalez- Aseguinolaza G, et al. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 2011;53:1864-1873.
5. Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillen ZP, Prieto J, et al. The fusion protein of IFN-alpha and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism. J Immunol 2012;188:3988-3992.
6. Menne S, Cote PJ. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 2007;13:104-124.
7. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995;69:6158-6169.
8. Berraondo P, Garcia-Navarro R, Gonzalez-Aseguinolaza G, Vales A, Blanco- Urgoiti B, Larrea E, et al. The woodchuck interferon-alpha system: Cloning, family description, and biologic activity. J Med Virol 2002;68:424-432.
9. Berraondo P, Ochoa L, Crettaz J, Rotellar F, Vales A, Martinez-Anso E, et al. IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. Mol Ther 2005;12:68-76.
10. Fioravanti J, Gomar C, Medina-Echeverz J, Otano I, Benito A, Prieto J, et al. Characterization of woodchuck apolipoprotein A-I: a new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model. J Med Virol 2011;83:1221-1229.
11. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003;7:839-850.
12. Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, et al. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 2008;52:3617-3632.
13. Cote PJ, Roneker C, Cass K, Schodel F, Peterson D, Tennant B, et al. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol 1993;6:161-169.
14. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102:96-104.
15. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-1228.
16. van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005;21:1163-1171.
17. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
18. Berraondo P, Crettaz J, Ochoa L, Paneda A, Prieto J, Troconiz IF, et al. Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction. Hum Gene Ther 2006;17:601-610.
19. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
20. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a doubleblind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309-319.